Diurnal Group plc announced that following 14 years with the Company, Martin Whitaker has decided to step down as Chief Executive Officer (CEO) and a member of the Board of Diurnal, with immediate effect, to enable him to pursue other business opportunities. Richard Bungay, currently the Company's Chief Financial Officer (CFO), who has been with the Company for more than five years, will immediately assume the role of Interim CEO until a successor is appointed. Additionally, David Bevan, who was appointed Interim Head of Commercial in November2021, has been promoted to the newly created role of Chief Business Officer.

David has over 30 years of pharmaceutical expertise with a broad base of general management, sales, marketing and commercial experience, in large and medium-sized pharmaceutical companies with Global, EU and UK responsibility.